http://rdf.ncbi.nlm.nih.gov/pubchem/patent/KR-102008490-B1
Outgoing Links
| Predicate | Object |
|---|---|
| classificationCPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K9-2833 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K9-0002 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K9-0053 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-685 |
| classificationIPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-661 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K9-20 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K9-22 |
| filingDate | 2013-01-14-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| grantDate | 2019-08-08-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationDate | 2019-08-08-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber | KR-102008490-B1 |
| titleOfInvention | Controlled release pharmaceutical composition comprising choline alfoscerate or pharmaceutically acceptable salt thereof and method for manufacturing the same |
| abstract | The present invention relates to a controlled release pharmaceutical composition comprising choline alfoscerate or a pharmaceutically acceptable salt thereof, wherein the blood concentration of the drug persists above the baseline for at least 6 hours after oral administration. |
| priorityDate | 2013-01-14-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type | http://data.epo.org/linked-data/def/patent/Publication |
Incoming Links
Total number of triples: 60.